Is pathogenetic therapy for type 2 diabetes possible?
https://doi.org/10.14341/probl200854550-57
Abstract
Diabetes mellitus (DM) continues to be a heavy burden for national health services around the world. It is one of the main causes of early disability and high mortality. Moreover, despite the adoption of national diabetes control programs in most countries of the world, its prevalence and incidence continues to increase not only among people over 40, but also among adolescents and children.
About the Authors
M. I. Balabolkin
Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
Ye. M. Klebanova
Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
V. M. Kreminskaya
Sechenov Moscow Medical Academy
Russian Federation
Russian Federation
References
1. Accilli D., Ardcn К. С. // Cell. - 2004. - Vol. 117. -P. 421-426.
2. American Association of Clinical Endocrinologist. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-managcment-2002 update // Endocr. Pract. - 2002. - Vol. 8. - Suppl. 1. - P. 40-82.
3. American Diabetes Association. Standards of medical care in diabetes // Diabetes Care. - 2007. - Vol. 30. - Suppl. 1. - P. S1-S103.
4. Bloomgarden Z. T. // Diabetes Care. - 2004. - Vol. 27. - P. 998-1010.
5. Canadian Diabetes Association. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada // Can. J. Diabets. - 2003. - Vol. 27. - Suppl. 2. - P. S1-S152.
6. Cline G. W., Petersen K. F, Krssak M. et al. // N. Engl. J. Med. - 1999. - Vol. 341. - P. 240-246.
7. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus // Arch. Ophthalmol. - 1995. - Vol. 113. - P. 36-51.
8. Egawa K., Nakashima N., Sharma P. M. et al. // Endocrinology. - 2000. - Vol. 141. - P. 1930-1935.
9. El-Assaad W., Buteau J., Peyot M. L. et al. // Endocrinology. - 2003. - Vol. 144. - P. 4154-4163.
10. European Diabetes Policy Group. A desktop guide to type 2 diabetes // Diabet. Med. - 1999. - Vol. 16. - P. 716-730.
11. Itoni S. I., Ruderman N. В., Schmieder F., Boden G. // Diabetes. - 2002. - Vol. 51. - P. 2005-2011.
12. Itoh Y., Kawamata Y., Harada M. et al. // Nature. - 2003. - Vol. 422. - P. 173-176.
13. Martins E. F., Miyasaka С. К., Newsholme P. et al. // Diabet. Metab. - 2004. - Vol. 30. - P. 21-27.
14. Moeschet K., Beck A., Weigert С. et al. // J. Diol. Chem. - 2004.- Vol. 279. - P. 25157-25163.
15. Morino K., Pedersen K. F., Dufour S. et al. // J. Clin. Invest. - 2005.- Vol. 115. - P. 3587-3593.
16. Mulder H., Yang S., Sorhede Winzell M. et al. // Diabetes. - 2004.- Vol. 53. - P. 122-128.
17. Nathan D. M., Вuse J. В., Davidson M. B. et al. // Diabetologia. - 2006. - Vol. 49. - P. 1711-1721.
18. Neschen S, Morino K., Hammond L. E. et al. // Cell. Metab. -2005. - Vol. 2. - P. 55-65.
19. Nolan С. J., Leahy J. L., Detghingaro-Augusto V. et al. // Diabetologia. - 2006. - Vol. 49. - P. 2120-2130.
20. Pappan K. L., Pan Z., Kwon G. et al. // J. Biol. Chem. - 2005.- Vol. 280. - P. 9023-9029.
21. Perseghin G., Ghosh S., Gerow K., Shulman G. I. // Diabetes. -1997. - Vol. 46. - P. 1001-1009
22. Perseghin G, Price Т. В., Petersen K. F. et al. N. Engl. J. Med. -1996. - Vol. 335. - P. 1357-1362.
23. Perseghin G, Sclfo P., De Cobelli F. et al. // Diabetes. - 1999. -Vol. 48.-P. 1600-1606.
24. Petersen K. F., Dufour S., Befroy D. et al. // N. Engl. J. Med. -2004. - Vol. 350. - P. 664-671
25. Ramanadham S., Song H., Bao S. et al. // Diabetes. - 2004. -Vol. 53. - Suppl. 1. - P. SI79-S185.
26. Roduit R., Nolan C, Alarcon С. et al. // Diabetes. - 2004. - Vol. 53. - P. 1007-1019.
27. Rothman D. L., Magnusson I., Cline G. et al. // Proc. Natl. Acad. Sci. USA. - 1995. - Vol. 92. - P. 983-987.
28. Ruderman N.. Prentki M. // Nat. Rev. Drug. Discov. - 2004. -Vol. 3.-P. 340-351.
29. Samuel V. Т., Liu Z. X, Qu X. Q. et al. // J. Biol. Chem. -2004. - Vol. 279. - P. 32345-32353.
30. Stratton I. M., AdlerA. L., Neil H. A. et al. // Br. Med. J. -2000. - Vol. 321. - P. 405-412.
31. Taniguchi С M., Emanuelli В., Kahn С .R. // Nat. Rev. Mol. Cell. Biol. - 2006. - Vol. 7. - P, 85-96.
32. UK Prospective Diabetes Study (UKPDS) Group. Effects of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - Vol. 352. - P. 854-865.
33. UK Prospective Diabetes Study (UKPDS) Group. Effects of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - Vol. 352. - P. 854-865.
34. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment of risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. -Vol. 352. - P. 837-853.
35. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin com-pared with conventional treatment of risk of complications in patients with type 2 diadetes (UKPDS 33) // Lancet. - 1998. -Vol. 352. - P. 837-853.
36. Weiss R., Dufour S., Taksali S. E. et al. // Lancet. - 2003. - Vol. 362. - P. 951-957.
37. Wild S., Roglic G, Green A. et al. // Diabetes Care. - 2004. -Vol. 27. - P. 1047-1053.
38. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complication- Part 1: Diagnosis and classification of diabetes mellitus. - Geneva: WHO, 1999.
39. Yu С.L., Chen Y., Cline G. W. et al. // J. Biol. Chem. -2002. - Vol. 277. - P. 50230-50236.
Review
For citations:
Balabolkin M.I., Klebanova Ye.M., Kreminskaya V.M. Is pathogenetic therapy for type 2 diabetes possible? Problems of Endocrinology. 2008;54(5):50-56. (In Russ.) https://doi.org/10.14341/probl200854550-57
Views:
1874
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
